RxDoctor Payments Data

Josephine Corona, MD

Family Medicine · Victorville, CANPI 1093248296

Payments from drug & device makers

$823in general payments, 2019–2025

Across 42 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$160
  • Novo Nordisk$141
  • Bayer$136
  • Merck$87
  • Lilly USA, LLC$84
  • Xeris Pharmaceuticals, Inc.$43
  • plus $173 from 8 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$823 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$28,812
Medicare patients
58
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$89,277
JardianceEmpagliflozin64$77,514
EliquisApixaban77$67,104
XifaxanRifaximin12$43,325
JanuviaSitagliptin Phosphate37$42,017
MyrbetriqMirabegron27$29,335
MounjaroTirzepatide26$28,293
TrulicityDulaglutide14$20,353
RybelsusSemaglutide18$20,091
XareltoRivaroxaban17$17,083
EntrestoSacubitril/Valsartan15$16,300
Lantus SolostarInsulin Glargine,hum.Rec.Anlog113$14,502
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog39$12,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,758
DapagliflozinDapagliflozin Propanediol11$6,350

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$141$109,36897 claims
PfizerEliquis$160$67,10477 claims
Lilly USA, LLCMounjaro, Trulicity$84$48,64640 claims
MerckJanuvia$87$42,01737 claims
GSKTrelegy Ellipta$19$12,75820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Victorville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →